Text full multimedia monochrome

First time here?

Find out more about how The Lecture List works.

Coronavirus situation update

Our lecture organisers may or may not have had time to update their events with cancellation notices. Clearly social gatherings are to be avoided and that includes lectures. STAY AT HOME FOLKS, PLEASE.


Find out what you can do to keep The Lecture List online

Enhancing Drug Quality: The benefits of kinetic and thermodynamic binding data in discovery

This event will look at how a detailed analysis of drug-protein binding thermodynamics and kinetics can significantly improve Lead and Clinical Candidate quality.

This symposium will cover the current thinking around the integration of thermodynamic- and kinetic-based approaches into Drug Discovery, how these approaches may relate to other measures of ‘Developability’ and how they may be used to identify Clinical Candidates with enhanced in vivo efficacy whilst reducing potential off-target adverse events.


Chris Kruse, Pharma Plexus | talks
Dirk Ullman, Evotec | talks
Stephen Roughley, Vernalis | talks
György Keserü, Gedeon Richter | talks
Helena Danielson, Beatica/Uppsala University | talks
Alan Brown, Pfizer | talks
Rob Cooke, Heptares | talks
Geoff Holdgate, AstraZeneca | talks


Date and Time:

6 November 2012 at 9:30 am


Full Day



15 Belgrave Square

More at SCI...



£110 SCI Member, £35 SCI Student Member, £70 SCI Subsidised Member, £145 Non Member

Available from:


Additional Information:

09.30 Registration and refreshments
09.55 Welcome and introduction
10.00 Target-drug interactions, Chris Kruse, Pharma Plexus
10.45 Biophysical techniques for measuring kinetic and thermodynamics of binding, Dirk Ullman, Evotec
11.30 Fragments: from the (k)off, Stephen Roughley, Vernalis
12.00 Lunch and exhibition
13.30 Thermodynamics guided lead discovery and optimisation, György Keserü, Gedeon Richter
14.15 Exploiting interaction kinetic analysis for lead discovery and optimization
Helena Danielson, Beatica/Uppsala University
14.45 Design of CRF1 antagonists with slow offset binding kinetics, Alan Brown, Pfizer
15.15 Refreshments
15.45 Application of structure-based approaches to the discovery of GPCR modulators, Rob Cooke, Heptares
16.15 Exploiting kinetics and thermodynamics in drug discovery, Geoff Holdgate, AstraZeneca
17.00 Open debate and closing remarks
17.20 Wine reception

Register to tell a friend about this lecture.


If you would like to comment about this lecture, please register here.


Any ad revenue is entirely reinvested into the Lecture List's operating fund